WINT (Windtree Therapeutics) Short Interest

View and export this data going back to 1984. Start your Free Trial

What is Windtree Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Windtree Therapeutics's Short Interest

For the Biotechnology subindustry, Windtree Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Windtree Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Windtree Therapeutics's Short Interest falls into.

Save Embed

;

Save Embed

;

Windtree Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Windtree Therapeutics Inc (NAS:WINT) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622

Website

https://www.windtreetx.com

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Executives

Craig Fraser	director, officer: Chief Executive Officer	AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Jamie Mcandrew	officer: VP, Controller, & CAO	WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Mark Strobeck	director	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
John P. Hamill	officer: SVP & CFO	4092 NEW HOPE ROAD, FURLONG PA 18925
Bioengine Capital Inc.	10 percent owner	7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503
Center Laboratories, Inc.	10 percent owner	7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503
Diane Carman	officer: SVP & General Counsel	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Eric Curtis	officer: SVP & COO	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Steven Simonson	officer: SVP, Chief Development Officer	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Evan Loh	director	75 KNEELAND STREET, BOSTON MA 02111
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Robert A Scott	director
Joseph M Mahady	director	16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005
Brian D Schreiber	director	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976